7 hasil untuk "Hao-Rui Shen"

EBV-Mir-BART5-5p targets p53 independent pathway in cytoplasm: Potential role in EBV lymphomagenesis

Wei-Ting Wang; Jing-Ran Guo; Li Wang dkk.

Genes and Diseases, Vol. 10 No. 4 · 2023 · Inggris · DOAJ Scopus

Revealing the heterogeneity of treatment resistance in less‐defined subtype diffuse large B cell lymphoma patients by integrating programmed cell death patterns and liquid biopsy

Wei Hua; Jie Liu; Yue Li dkk.

Clinical and Translational Medicine, Vol. 15 No. 1 · 2025 · Inggris · DOAJ Scopus

Abstract Precision medicine in less‐defined subtype diffuse large B‐cell lymphoma (DLBCL) remains a challenge due to the heterogeneous nature of the disease. Programmed cell death (PCD) pathways are crucial in the advancement of lymphoma and serve as significant prognostic markers for individuals…

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution

Jin-Hua Liang; Yi-Fan Wu; Si-Ying Pan dkk.

BMC Medicine, Vol. 24 No. 1 · 2026 · Inggris · DOAJ Scopus

Abstract Background Circulating tumor DNA (ctDNA) profiling offers a noninvasive approach to monitor minimal residual disease (MRD) and clonal evolution in diffuse large B-cell lymphoma (DLBCL). Methods In this study, we analyzed 164 newly diagnosed DLBCL patients from the First Affiliated Hospital…

SH3GL1‐activated FTH1 inhibits ferroptosis and confers doxorubicin resistance in diffuse large B‐cell lymphoma

Zi‐Wen Duan; Wei‐Ting Wang; Yan Wang dkk.

Clinical and Translational Medicine, Vol. 15 No. 3 · 2025 · Inggris · DOAJ Scopus

Abstract Background Diffuse large B‐cell lymphoma (DLBCL) is predominant subtype of non‐Hodgkin lymphoma and can be effectively treated. Nevertheless, a subset of patients experiences refractory or relapsed disease, highlighting the need for new therapeutic strategies. Methods Depmap database based…

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial

Hao-Rui Shen; Jia-Zhu Wu; Hua Yin dkk.

Blood Cancer Journal, Vol. 16 No. 1 · 2026 · Inggris · DOAJ Scopus

Abstract This clinical trial (NCT05347641) evaluated efficacy and safety of penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in patients with newly diagnosed (ND) primary central nervous system lymphoma (PCNSL). Patients received an induction treatment of six…

Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial

Jin-Hua Liang; Tong-Yao Xing; Wei-Ying Gu dkk.

BMC Medicine, Vol. 24 No. 1 · 2026 · Inggris · DOAJ Scopus

Abstract Background This phase II clinical trial evaluated the R2-GemOx-PD1i regimen, a combination of penpulimab (a modified PD1 inhibitor) with lenalidomide and rituximab, gemcitabine, and oxaliplatin, in treating refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL). Methods…

Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms

Kai-Xin Du; Yi-Fan Wu; Wei Hua dkk.

Cell Communication and Signaling, Vol. 22 No. 1 · 2024 · Inggris · DOAJ Scopus

Abstract TP53 mutation (TP53-mut) correlates with inferior survival in many cancers, whereas its prognostic role in diffuse large B-cell lymphoma (DLBCL) is still in controversy. Therefore, more precise risk stratification needs to be further explored for TP53-mut DLBCL patients. A set of 2637…